Alpha Tau Medical Ltd. develops Alpha DaRT, an intratumoral alpha-radiation therapy being studied for solid tumors. News about DRTS centers on clinical development, regulatory interactions and scientific presentations for Alpha DaRT across oncology programs including recurrent cutaneous squamous cell carcinoma, pancreatic cancer, recurrent glioblastoma, and head and neck cancer.
Company updates frequently cover trial data, feasibility and safety findings, patient enrollment milestones, FDA device-pathway activity, conference abstracts and global study expansion. The news also reflects the company's focus on localized alpha-emitter radiation intended to treat tumors while limiting exposure to surrounding tissue.
Alpha Tau Medical (Nasdaq: DRTS) signed a memorandum of understanding with Samsung Medical Center to explore a pancreatic cancer trial in South Korea.
The potential study at the Seoul hospital would be Alpha DaRT’s first clinical trial in South Korea. Any trial remains subject to regulatory and ethics committee approvals; the agreement concerns exploring a study rather than starting one. Alpha Tau said adding Korea could potentially extend its pancreatic cancer program to six countries across North America, Europe, the Middle East and Asia.
Alpha DaRT is an investigational radiation treatment designed to deliver radium-224 sources directly into solid tumors. Samsung Medical Center plans to review the treatment’s clinical application under the exploratory collaboration.
Alpha Tau Medical (Nasdaq: DRTS) received FDA approval to expand its U.S. REGAIN trial of Alpha DaRT for recurrent glioblastoma. The approved Investigational Device Exemption supplement increases enrollment from 10 to up to 20 patients across three authorized U.S. academic cancer centers. It also permits patients with IDH-mutant grade 4 tumors, adds progression-free survival—time without disease worsening—as a secondary endpoint, and introduces regular quality-of-life assessments.
The protocol adds an interim analysis six months after the fifth patient's treatment, which occurred in July 2026. New REGAIN data will be presented at the Society for Neuro-Oncology meeting on November 13, 2026, building on previously announced interim results from the first three treated patients. Alpha Tau believes the expanded trial could generate additional data that may support market submission requirements in recurrent glioblastoma.
Alpha Tau Medical (NASDAQ: DRTS) announced that its management will participate in two investor conferences in October 2026.
Management will hold 1x1 meetings at Fall Focus: Barclays Biotech 1x1 Day in New York on October 6. The company will give a presentation at the Investment Generation Conference in Rishon Letzion, Israel, on October 15, from 12:30 to 1:00 PM.
Alpha Tau Medical (DRTS) announced that CFO Raphi Levy will participate in two investor conferences in September 2026 in New York.
He will hold 1x1 meetings at Citi's 2026 Biopharma Back to School Conference on Wednesday, September 9, 2026. He will also take part in a fireside chat and 1x1 meetings at the H.C. Wainwright 28th Annual Global Investor Conference on Monday, September 14, 2026, from 9:30–10:00AM ET. Interested investors are asked to contact Citi or H.C. Wainwright representatives to schedule meetings.
Alpha Tau (Nasdaq: DRTS) reported completion of patient enrollment in its multicenter IMPACT pilot study evaluating intratumoral Alpha DaRT® plus first-line chemotherapy for newly diagnosed, unresectable locally advanced or metastatic pancreatic adenocarcinoma. Enrollment was expanded three times, from 12 to 48 patients, following strong interest from patients and clinicians.
Alpha DaRT is administered once alongside standard first-line regimens (mFOLFIRINOX or gemcitabine + nab-paclitaxel), an approach supported by a favorable safety profile from earlier Israeli and Canadian studies. According to Alpha Tau, initial IMPACT data are targeted for early 2027 to inform a planned pivotal study and support its broader global pancreatic cancer program, including the ACAPELLA trial in France and a study at the University of Verona.
Nano Dimension (Nasdaq: NNDM) appointed Nadav Kidron to its Board of Directors and plans to form a new Strategy and Capital Allocation Committee as part of an ongoing strategic review led by Chairman Phillip Borenstein.
Kidron, President and CEO of Oramed Pharmaceuticals (Nasdaq: ORMP) and a director at Alpha Tau Medical (Nasdaq: DRTS) and Lifeward (Nasdaq: LFWD), will chair the committee. According to Nano Dimension, the committee will help evaluate capital allocation alternatives, potential returns of excess capital to shareholders, monetization of non-core assets and other strategic opportunities aimed at maximizing long-term shareholder value.
Alpha Tau (NASDAQ: DRTS) reported second quarter 2026 results and a major corporate update, highlighting rapid clinical and commercial progress for its Alpha DaRT cancer therapy. The company entered a 20‑year U.S. prostate cancer collaboration with Tolmar, including a $20 million equity investment at a 25% premium, $15 million for a new U.S. manufacturing facility, and up to $161.5 million in potential milestones, plus future supply at 60% of net sales.
Key clinical updates included 100% local disease control and 67% complete response in the U.S. REGAIN recurrent glioblastoma trial, full enrollment of the 88‑patient ReSTART pivotal cSCC study, strong pancreatic cancer survival data, and a 100% objective response rate with 18.2‑month median overall survival in a head and neck cancer combination study. Cash and deposits rose to $104.8 million, while the six‑month net loss widened to $68.8 million due largely to non‑cash warrant remeasurement.
Alpha Tau (Nasdaq: DRTS) plans to dual-list its ordinary shares on the Tel Aviv Stock Exchange (TASE), alongside Nasdaq. According to Alpha Tau, it has filed to register 92,478,154 outstanding shares plus various potential future shares from convertible securities, option pools and its employee share purchase plan. The shares are expected to trade on TASE under the English symbol DRTS and the Hebrew symbol דרטס.
Alpha Tau (Nasdaq: DRTS) reported clinical data for Alpha DaRT® combined with pembrolizumab in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma. In a single-center, open-label study, 9 evaluable patients achieved a 100% systemic objective response rate, with 4 complete and 5 partial responses.
According to Alpha Tau, median overall survival reached 18.2 months and median progression-free survival 5.4 months, compared with historical pembrolizumab monotherapy benchmarks of 12.3 and ~3.2 months. No Alpha DaRT-related serious adverse events were seen; only two Grade 1 events occurred. The Simon two-stage design’s success threshold (more than six responders) was surpassed, recruitment was completed at 11 patients, and the company is discussing a larger U.S. study with the FDA. Alpha Tau cautions against direct comparisons with unrelated trials.
Alpha Tau (Nasdaq: DRTS) reported the first successful treatment of an immunocompromised patient with recurrent cutaneous squamous cell carcinoma (cSCC) in its ADMIRE clinical study, evaluating intratumoral Alpha DaRT therapy for this high‑risk group. The procedure was performed at Banner MD Anderson Cancer Center in Gilbert, Arizona, by Dr. Michael Samuels and Dr. Thomas Shellenberger.
ADMIRE targets immunocompromised patients, including organ transplant recipients, those with hematologic malignancies or on chronic immunosuppressive therapy, who face up to a 65–100‑fold higher cSCC incidence and limited treatment options. The trial builds on experience from Alpha Tau’s ReSTART pivotal study for recurrent cSCC, which recently completed enrollment.